P47.09 Tepotinib + Osimertinib for EGFR-Mutant NSCLC with Resistance to First-Line Osimertinib Due to MET amplification: INSIGHT 2

Saved in:
Bibliographic Details
Published in:Journal of thoracic oncology 2021-10, Vol.16 (10), p.S1099-S1100
Main Authors: Dooms, C., Nadal, E., Raskin, J., Demedts, I., Mazieres, J., Wislez, M., Abdul, S., Mun, T.L., Wang, C., Viteri, S., Le, X., How, S.H., Tan, D., Takeda, M., Veillon, R., Karachaliou, N., Ellers-Lenz, B., Smit, E., Wu, Y.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2021.08.502